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Abstract
Background: The need for safe and effective treatment of dengue virus (DEN), a class A agent
that causes dengue hemorrhagic fever/dengue shock syndrome, has been a critical global priority.
An effective vaccine for DEN is not yet available. In this study the possibility of attenuating DEN
infection using adeno-associated virus (AAV)-encoded short interfering RNAs (siRNA) was
examined in Vero cells and human dendritic cells (DCs).
Methods: A cassette encoding siRNA targeted to a 3' untranslated sequence common to all DEN
serotypes was designed and tested for its ability to attenuate DEN infection by use of AAV delivery.
Results:  Vero cells or DCs infected with AAV-siRNA showed a significant, dose-dependent
reduction in DEN infection. Treatment of DCs with AAV-siRNA also decreased the DEN-induced
apoptosis of DCs and did not induce significant inflammation.
Conclusion: These results demonstrate that AAV-mediated siRNA delivery is capable of reducing
DEN infection in cells and may be useful in decreasing DEN replication in humans.
Introduction
The need for a safe and effective prophylaxis or treatment
for dengue virus (DEN) infection, a category A mosquito-
borne human pathogen, is a critical global priority. DEN
causes dengue hemorrhagic fever/dengue shock syndrome
(DHF/DSS), which is associated with heterologous sec-
ondary DEN infection and affects thousands of people
worldwide. The incidence of DHF/DSS is increasing in the
western hemisphere and, although many different
approaches are being tried to develop prophylactic DEN
vaccines, none have been licensed for public health and
there are no specific antiviral treatments available.
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DEN belongs to the family of Flaviviruses and is an envel-
oped single plus-stranded RNA virus with four distinct
serotypes. The DEN genome of approximately 11,000
nucleotides encodes a polyprotein (C-prM-E-NS1-NS2a-
NS3-NS4a-NS4b-NS5) consisting of three structural pro-
teins (C, prM and E) and seven nonstructural proteins.
The open reading frame is flanked by a 100 nucleotide-
long noncoding region (NCR) at the 5' end and a 400 to
600 nucleotide-long NCR at the 3'end [1]. Although the
mechanism of DEN pathogenesis is unclear, DEN typi-
cally appears to replicate locally in skin or blood dendritic
cells (DCs) and may also involve monocytes and macro-
phages. Secondary infection is usually more serious
because of antibody-dependent enhancement (ADE).
We reasoned that an effective antiviral approach aimed at
attenuating the DEN virus burden might protect infected
subjects from DHF/DSS and, therefore, we examined the
potential of an in vivo gene-silencing approach using short
interfering RNA (siRNA) to decrease DEN replication.
RNA interference is triggered by dsRNA that is cleaved by
an RNAse-III-like enzyme, Dicer, into 21–25 nucleotide
fragments with characteristic 5' and 3' termini [2]. These
siRNAs act as guides for a multi-protein complex, includ-
ing a PAZ/PIWI domain containing the protein
argonaute2, that cleaves the target mRNA [3]. These gene-
silencing mechanisms are highly specific and can poten-
tially inhibit the gene expression of different viruses [4,5].
This approach was found to be effective in blocking DEN
replication in insect cells [6,7].
Plasmid DNAs or adenoviruses encoding appropriate
DNA sequences allow transient siRNA expression in cells
and in vivo leading to specific gene silencing. However,
plasmids transfect mammalian cells poorly, and adenovi-
ruses produce an acute inflammatory response and an
immune response to viral vector-encoded antigens [7,8].
We therefore developed an adeno-associated virus (AAV)
system capable of expressing siRNA cassettes, and tested
this vector with a siRNA cassette composed of a nucleotide
sequence from the 3' NCR of the DEN genome
(siDEN3UT), which is common to all four serotypes. The
results obtained in Vero cells and human DCs infected
with AAV-siDEN3UT show significant decreases in DEN
infection and DEN-induced apoptosis.
Methods
Plasmid constructs
The pCMV-MCS plasmid (Stratagene) was digested with
Not I and the larger fragment was ligated to the synthetic
adapter containing in order, Not I-Kpn I-Apa I-Xho I-Hind
III-EcoR I-Bam HI-Sac II-Sac I-Cla I-Sal I-Bgl II-Not I. The
U6 promoter was obtained by PCR amplification, using
specific primers with the desired restriction sites from the
template pSilencer 1.0-U6 (Ambion), and inserted into
the adaptor at the Kpn I and Apa I sites to get a novel plas-
mid pCMV-U6.
Pairs of oligos were synthesized to develop siRNA con-
structs. The nucleotide sequence for each siRNA is as fol-
lows: siEGFP: 5'-GGC GAT GCC ACC TAC GGC AAG CTT
CTC GAT TCG AAG CTT GCC GTA GGT GGC ATC GCC
CTT TTT G-3' [10]; siRSVNS1:5'-GGC AGC AAT TCA TTG
AGT ATG CTT CTC GAA ATA AGC ATA CTC AAT GAA
TTG CTG CCT TTT TG-3'; siDENPrM: 5'-GGA AGA CAT
AGA TTG TT G GTG CAC TCG AGT CAA CGT GCA CCA
ACA ATC TAT GTC T TC CCT TTT TG-3'; siDEN3UT:5'-
GGA AAA ACA GCA TAT TGA CGC TGC TCG AGT CAA
CGC AGC GTC AAT ATG CTG TTT TTC CCT TTT TG-3'.
Each pair of oligos was annealed and then inserted into
pCMV-U6 digested with Apa  I/Xho  I and Xho  I/EcoR  I
respectively. The modified pCMV-U6 plasmid was then
redigested with Not I and the smaller fragment was ligated
to the 2.9 kb fragment of pAAV-MCS (Stratagene)
obtained following its Not I digestion to generate the cor-
responding si-vector for EGFP, RSV and DEN. HEK-293
cells were cotransfected with the helper plasmid and the
si- plasmid to generate recombinant AAV.
Cell culture and viral packaging
HEK293 cells were cultured with DMEM (Cellgro) plus
10% FBS (Cellgro) and cotransfected with pSMWZ-
siDEN, pHelper and pAAV-RC (Stratagene) by standard
calcium phosphate transfection. Cells were harvested 48
hr post-transfection and the cell pellets were stored at -
80°C.
Purification of recombinant adenoassociated viruses
Cells were lysed by 5 cycles of freezing and thawing to
release the virus. Crude viral lysate were collected by cen-
trifugation at 27,000 × g for 30 min, and the supernatants
were harvested and put onto a CsCl gradient (density
1.20/1.50) in fresh tubes and centrifuged for 16 h at
100,000 × g. Opalescent bands were collected after ultra-
centrifugation. Titers of purified AAVs were measured
using an AAV titration ELISA kit (Progen Biotechnik,
Germany).
Isolation and culture of dendritic cells from human 
peripheral blood
Conditions were similar to those described previously
[11]. Buffy coats were diluted with one volume of DMEM
(Cellgro) and PBMCs were isolated by density-gradient
centrifugation using Histopaque-1077 (SIGMA) accord-
ing to the instructions. The PBMC layer was harvested,
washed twice with DMEM, resuspended in DMEM sup-
plemented with 10% FBS, and then seeded into six-well
culture plates. After 2 h at 37°C/5%CO2 the nonadherent
cells were removed and the adherent cells were cultured
with fresh DMEM supplemented with 10% FBS (Cellgro),Genetic Vaccines and Therapy 2004, 2:8 http://www.gvt-journal.com/content/2/1/8
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200 ng/ml IL-4 (BD-Pharmingen) and 50 ng/ml GM-CSF
(BD-Pharmingen) for 7 days prior to infection with DEN.
Blocking dengue virus infection in vitro
1 × 105 Vero cells or DCs were seeded into six-well tissue
culture plates and infected with different numbers of
recombinant AAV carrying the DEN-siRNA silencing cas-
sette. After 2 days the cells were infected with DEN-2 virus
(strain16803) at an MOI of 0.1.
Flow cytometry
Cells were harvested and centrifuged for 10 min at 150 ×
g. The cell pellets were washed with PBS and resuspended
with antibody to DEN-2 virus envelope protein, (Micro-
bix Biosystems Inc, Clone No 3H5) on ice for 40 min. The
cells were centrifuged and pellets were washed with PBS
and then resuspended with secondary antibody conju-
gated with FITC (Sigma) for an additional 30 min. The
number of infected cells was measured by flow cytometry
5 days post-infection. DCs were also stained with CD11c
antibody conjugated with PE (BD-Pharmingen).
Plaque assay
The supernatants from DEN-2-infected DCs were col-
lected at day 5 post-infection and 10-fold serial dilutions
were allowed to adsorb to monolayers of Vero cells in six-
well culture plates for 2 h. The medium was then removed
and replaced by an agarose-containing overlay (2X
DMEM, 10%FBS, non-essential amino acids (Gibco BRL),
1% low melting-point agarose (Gibco BRL) and the plates
were incubated at 37°C/5% CO2 for 5 days. Afterwards,
1% neutral red (Sigma) was added to each well and the
plaques were counted 48 h later.
Apoptosis assay
Infected-DCs were harvested on day 5 of infection with
DEN-2 virus. Aliquots of DCs were put onto slides using a
Cytospin and fixed with 4% paraformaldehyde. Apoptotic
DCs were determined using the terminal dUTP nick end-
labeling assay (TUNEL, Promega, Madison WI) and the
annexin V apoptosis detection kit (BD Biosciences, CA).
Cytometric bead array and ELISA analysis
Supernatants from infected-DCs were harvested at 24 h,
48 h, 72 h and 96 h post-infection. Cytokine concentra-
tions were measured by cytometric bead array (CBA) and
ELISA (BD-Pharmingen) following instructions in the
manuals.
Statistical analysis
Data were expressed as arithmetic mean ± SEM. Levels of
significance of the differences between groups were deter-
mined by the student t test. Values of p < 0.05 were con-
sidered statistically significant.
Results
Development of an AAV-siRNA system for gene silencing
In order to develop an AAV-siRNA system, a plasmid
pSMWZ-1 was engineered that comprised a mouse U6
promoter linked to a siRNA cassette (Fig. 1A). To test
whether this plasmid was functional and capable of sup-
pressing gene expression, HEK293 cells were cotransfected
with pEGFP, a plasmid expressing green fluorescent pro-
tein, and pSMWZ-siEGFP. The percentage of cells express-
ing EGFP was determined and the results showed that
there was a dose-dependent silencing of EGFP expression
(Fig. 1B). In contrast, control cells cotransfected with
siRSVNS1 (targets the NS1 gene of human respiratory syn-
cytial virus) in place of siEGFP did not show any reduc-
tion in EGFP expression. To test various siDEN
candidates, Vero cells were transfected with either
pSMWZ-siDENpreM (siDENpreM) or pSMWZ-
siDEN3UT(siDEN3UT), then two days post-transfection
infected with DEN-2 (strain 16803) at an MOI of 0.1. At
five days post-infection, the numbers of DEN-2 virus-
infected cells were quantified by fluorescence microscopy
using antibody to DEN-2 envelope protein and FITC-con-
jugated secondary antibody. The results showed that
siDEN3UT was better than siDENpreM in suppression of
DEN-2 infection (Fig. 1C). The AAV-siRNA system was
similarly tested using HEK293 cells which were infected
with AAV-siEGFP and then transfected with pEGFP. The
decrease in the percentage of cells expressing EGFP
showed that there was a silencing of EGFP expression in a
dose-dependent and sequence-specific manner (Fig. 1D).
To test whether AAV-siDEN-2 expression decreases DEN-
2 virus infection in cultured Vero cells, cells were infected
with recombinant AAV carrying siDEN-2 (MOI 10) or
siEGFP (MOI ~1000) silencing cassettes. After 2 days the
cells were infected with DEN-2 virus at an MOI of 0.1. Five
days later, the numbers of DEN-2 virus infected cells were
quantified by flow cytometry using anti-DEN-envelope
protein. Cells pre-infected with AAV-siDEN3UT, but not
AAV-siEGFP, showed a significant reduction in DEN infec-
tion, and the reduction was dose dependent (Fig. 2).
siRNA suppresses DEN infection in human dendritic cells
DEN is transmitted through Aedes aegypti mosquito bites,
and resident skin DCs are regarded as the targets of DEN
infection [12]. DCs are thought to be 10-fold more per-
missive for DEN infection than monocytes or macro-
phages [13]. We therefore tested the ability of AAV-
siDEN3UT to attenuate DEN infection in human DCs.
DCs were isolated from human blood and cultured in the
presence of IL-4 and GM-CSF for 5 days to generate imma-
ture DCs (iDCs). These DCs were then infected with 109
PFU/ml of recombinant AAV carrying siDEN3UT or
siEGFP (control) silencing cassette. After 2 days the cells
were infected with DEN-2 at an MOI of 0.1. Five daysGenetic Vaccines and Therapy 2004, 2:8 http://www.gvt-journal.com/content/2/1/8
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later, the numbers of DEN-2 infected cells were quantified
by flow cytometry using DEN-2 antibody. Cells prein-
fected with AAVsiDEN3UT showed a 50% reduction in
the number of infected cells (Fig. 3A). To test whether the
reduction in the number of infected DCs involved a reduc-
tion in DEN titer, the culture supernatants were examined
using a Vero cell-based plaque assay. AAV-mediated
siDEN3UT expression significantly decreased DEN-2 virus
Construction and characterization of the siDEN suppressor Figure 1
Construction and characterization of the siDEN suppressor. (A) Diagram of the construction of the plasmid vector, pSMWZ-
1, capable of expressing a DEN infection suppressor cassette. Abbreviations: N*, Not I; K, Kpn I; A, Apa I; E, EcoR I; SUP-1, 
Suppressor cassette; (B) Co-transfection with pSMWZ-siEGFP and pEGFP inhibits the expression of EGFP in cultured cells. 
HEK293 cells were transfected with different concentrations of plasmid DNA and three days later, EGFP-positive cells were 
counted by fluorescence microscopy. Results are expressed as mean ± SEM. *p < 0.05 compared to control (siRSVNS1, an 
unrelated siRNA construct against respiratory syncytial virus). (C) pSMWZ-siDEN suppression of DEN-2 virus replication. 
Vero cells were transfected with pSMWZ-siDEN3UT or pSMWZ-siDENpreM plasmid. Two days later, the cells were infected 
with DEN-2 virus (MOI of 0.1) and 5 days later, the numbers of DEN-2 virus infected cells were counted by fluorescence 
microscopy. Data are mean ± SEM. *p < 0.05 compared to control DEN-2. (D) AAV-siEGFP inhibits the expression of EGFP in 
cultured cells. HEK293 cells were infected with different concentrations of AAV-siEGFP, and three days later the cells were 
transfected with pEGFP. EGFP-positive cells were counted by fluorescence microscopy. Statistically significant differences, **p 
< 0.01, when compared to pEGFP plasmid control, AAV-siRSV (107) and AAV-siEGFP (108) group, respectively.
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titer compared to control (Fig. 3B). These results indicate
that AAV-siDEN3UT can significantly decrease DEN titers
in human DCs.
Silencing DEN-2 genes inhibits apoptosis in dendritic cells
It has been reported that DEN infection induces apoptosis
of DCs [11] leading to an immunosuppressed condition.
To examine the effect of AAV-mediated siRNA delivery in
DCs, apoptosis was investigated in infected DCs using the
TUNEL assay. The results showed that a small percentage
of DCs undergo apoptosis naturally during culture, but
DEN infection causes much more apoptosis. The AAV-
siRNA-treated DEN-infected DCs showed significantly
fewer apoptotic cells compared to DEN-infected cells
without AAV-siRNA (Fig. 4).
Differential expression of cytokines by infected dendritic 
cells
The supernatants of infected DCs were collected at differ-
ent time points and cytokines were measured using
cytokine bead array (CBA) and ELISA assays. As showed in
Figure 5, cultured DCs spontaneously produced increased
IL-1b. A variety of cytokines including IFN-γ, TNF-α, IL-8,
IL-6, IL-12 were measured (data not shown). In the pres-
ence of AAV-siRNA infection, the production of IFN-γ,
TNF-α, IL-8, IL-6, and IL-12 did not change significantly
AAVsiDEN expression decreases DEN-2 virus infection in cultured Vero cells Figure 2
AAVsiDEN expression decreases DEN-2 virus infection in cultured Vero cells. Cells were infected with different amounts 
(PFU/ml) of AAV carrying the siDEN3UT silencing cassette and after 2 days the cells were infected with DEN-2 virus (MOI of 
0.1). Five days later, the numbers of DEN-2 virus infected cells were measured by flow cytometry.
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compared with cultured DCs. IL-1b secretion at 72 h post-
infection was increased, however. These results indicate
that in our system, AAV-siRNA delivery does not induce
acute inflammation in DCs, in vitro,
Discussion
The significant findings of this report include the develop-
ment of an adeno-associated virus-based siRNA approach
for downregulating gene expression. A recombinant AAV-
siDEN3UT was utilized to induce significant decreases in
DEN infection compared to control in both Vero cells and
human DCs. The results indicate that siRNAs may be used
to attenuate DEN infection in human DCs and may have
therapeutic value.
Interference of gene expression by siRNAs is a novel strat-
egy to knock down specific genes in cells or tissues, and
the specific silencing of pathogen genes using siRNA is a
very attractive approach for the clinical treatment of infec-
tious diseases. Long dsRNAs (of >30 nt in length) activate
a dsRNA-dependent protein kinase and 2', 5'-oligoade-
nylate synthetase in mammalian cells, which leads to a
Suppression of DEN-2 replication in DCs by siDEN Figure 3
Suppression of DEN-2 replication in DCs by siDEN. (A) DCs were isolated from human peripheral blood and cultured in 
DMEM medium supplemented with FBS, IL-4 and GM-CSF. Non-adherent DCs were harvested on day 7, infected with AAVsi-
DEN, and two days later the cells were infected with DEN-2 at 0.1 MOI. DCs were harvested 5 days after DEN-2 infection and 
DEN-2 titers were measured by flow cytometry. (B) Supernatants from DEN-infected DCs were collected and added to cul-
ture plates containing confluent Vero cell monolayers. After virus adsorption, the Vero cells were overlaid with agarose and 
stained with 1% neutral red. Viral plaques were counted 48 h after neutral red overlay. Data are the averages of two independ-
ent experiments. *p < 0.05 compared to control.
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non-specific reduction in levels of mRNAs [14]. The
endogenous expression of siRNAs from introduced DNA
templates is thought to overcome some limitations of
exogenous siRNA delivery, in particular its transient
effects on silencing specific genes and loss of phenotype
[15]. AAV vectors have been proven to be safe and
efficacious in Phase I clinical trials for gene therapy of
cystic fibrosis and hemophilia B and are regarded as a
potential alternative to retroviral and adenoviral vectors
for gene therapy in humans. The AAV vectors have a
number of advantages over other vectors. They are not
pathogenic and do not induce production of neutralizing
antibodies that could reduce transgene function. They
possess a broad-range of tissue tropism and the capability
of inducing long-term transgene expression [16]. In this
study, we utilized a novel AAV system to deliver DEN
siRNA into mammalian cells and estimated its anti-DEN
effect in vitro. In this AAV system, we incorporated the
mouse U6 promoter, which is important for transcription
and folding of the suppressor RNA, into a plasmid pCMV-
U6.
The choice of appropriate target genes is necessary for the
success of the siRNA strategy, and two siRNAs derived
from either the pre-M or the 3' NCR region of DEN-2 were
used in our study. An internal deletion of 3' NCR nucle-
otide sequences was found to be lethal for DEN virus rep-
lication in an in vivo study [17]. The 3' NCR of the
AAVsiDEN reduces apoptosis in human DCs infected with DEN-2 Figure 4
AAVsiDEN reduces apoptosis in human DCs infected with DEN-2. DCs were isolated from human peripheral blood and 
infected with AAVsiDEN followed by DEN-2. Five days after infection, DCs were put onto slides and apoptosis was deter-
mined using the terminal dUTP nick end-labeling assay (TUNEL). Nuclei were stained with diamidinophenylindole (DAPI). Rep-
resentative fields were visualized by fluorescence microscopy.
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flavivirus genome, which presumably functions as a pro-
moter for minus-strand RNA synthesis, is predicted to
form a stem-and-loop secondary structure. Computa-
tional analyses have revealed that there is conserved
sequence in all flaviviruses within the 3' end [18,19].
Thus, two siRNA cassettes were tested in this study that
included the 3'NCR sequence common to all four DEN
serotypes. The other siRNA cassette is from the gene
encoding the preM protein which is important for matu-
ration of the virus into an infectious form. Our test of anti-
DEN efficiency showed that siDEN3UT attenuated DEN
Infection better than siDENpreM. Knocking down viral
genes at the earlier stage of the viral multiplication cycle
rather than in the structural protein synthesis phase may
provide better antiviral protection, although the limited
plasmid transfection ratio appeared to influence the sup-
pression efficiency of siDEN to DEN-2 infection in Vero
cells in the present study (Fig. 1C). The other DEN sero-
types will be investigated with our 3'NCR cassette.
DEN is transmitted through Aedes aegypti mosquito bite,
and resident skin DCs are an early target of DEN infection
[12]. Immature DCs are the most permissive for DEN
infection and serve as a source of DEN replication and
production [20]. Replication in the early target cells may
be essential for dengue pathogenesis in the human host.
In this study, we also utilized peripheral blood iDCs as a
cell model to test our AAV system. Similar to results in
Vero cells, AAV-mediated siDEN3UT delivery down-regu-
lated DEN-2 protein expression in iDCs. However, the
magnitude of suppression in iDCs at the same infectious
titer of AAV-siDEN was less compared to that found in
Differential expression of cytokines in the supernatants of infected DCs Figure 5
Differential expression of cytokines in the supernatants of infected DCs. Supernatants from DEN-2-infected DCs with or with-
out siDEN treatment were harvested at the indicated time points and analyzed by CBA and ELISA to measure the concentra-
tions of cytokines. Data are the averages of two independent experiments. **p < 0.01 in comparison with the value of DCs 
within individual group.
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Vero cells. Previous data showed that variations in the effi-
ciency of transduction among DCs derived from different
normal blood donors is between 2% and 50% [21], and
we found that the infectious ratio for AAVEGFP is about
45%~50% in Vero cells. That may be due to limited
expression of the AAV receptor or differential activation of
the mouse U6 promoter in Vero cells compared to DCs
[22]. Increasing the AAV infection titer or utilizing a more
effective promoter within the AAV vector backbone might
elevate the suppression for DEN replication in iDCs. Nev-
ertheless, DCs treated with recombinant AAV showed a
significant reduction in DEN virus titer compared to con-
trol. This is important as viral titer is the gold standard for
measuring antiviral activity.
DCs are one of the most powerful of APCs. After infection
with virus in the periphery, iDCs process viral antigens,
then differentiate into mature DCs and migrate from
peripheral tissues to lymph nodes where they prime naïve
CD4 and CD8 T lymphocytes to maintain protective anti-
viral cytotoxic T cell memory [23,24]. Thus, DCs play an
important role in the initiation of antiviral immunity and
provide a crucial step in the development of adaptive anti-
viral immunity. Previous data showed that DEN infection
induces apoptosis of DCs [11], which leads to a state of
temporary immune-suppression during DEN fever. An
important observation in our study is that AAV-siDEN
treatment resulted in a significant decrease in apoptotic
iDCs. The attenuation of apoptosis in iDCs following
AAV-mediated siRNA delivery suggests that AAV-siRNA
may be immunologically protective. After the primary
DEN infection, most patients appear viremic in the early
febrile phase, but the viruses are quickly cleared from the
blood system after defervescence [25]. The activation of
both a humoral and cellular immune response is consid-
ered to be involved in DEN clearance. The most severe
outcome in DEN infection is development of DHF/DSS,
which is associated with secondary infections by hetero-
typic DEN serotypes. It is postulated that the preexisting,
cross-reactive, adaptive immune response leads to exces-
sive cytokine production, complement activation, and the
release of other inflammatory factors that produce DHF/
DSS [20]. Therefore, it should be imperative for prophy-
laxis of DHF/DSS to eliminate DEN infection by different
serotypes in the early target cells. Attenuation of DEN
infection in DCs and protection of infected DCs from
apoptosis would be a benefit for the elimination of the
early DEN infection and the development and mainte-
nance of antiviral innate/adaptive immune response in
vivo.
One of the important features of AAV vectors is the lack of
inflammation following infection. We failed to detect sig-
nificant IFNγ or IL-12 production in the supernatants of
AAV-siDEN-infected DCs. This is in accordance with pre-
vious data [26-28], which demonstrated our AAV delivery
system did not induce significant acute inflammatory
responses and, therefore, is useful in gene therapy for
DEN infection in humans.
In conclusion, we developed a novel AAV-mediated
siRNA delivery system. Our results demonstrate signifi-
cant downregulation of DEN protein expression in Vero
cells and human DCs, which strongly suggest that our
AAV vector can be useful for siRNA delivery and that this
AAV system may be applied in clinical settings to attenu-
ate DEN infection.
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